Intelligent Bio Solutions Announces $10 Million At-the-Market Offering Under Nasdaq Rules

Intelligent Bio Solutions Inc. (Nasdaq: INBS), a medical technology company specializing in intelligent, rapid, and non-invasive testing solutions, has announced a significant financing move to support its growth and operational initiatives. On December 31, 2025, the company disclosed entering into a securities purchase agreement for a $10.0 million private placement priced at-the-market (ATM) under Nasdaq rules. This strategic capital raise is designed to provide the company with flexible funding by allowing it to sell shares incrementally at prevailing market prices, rather than at a fixed price, thereby optimizing capital access in alignment with market conditions.

The ATM offering mechanism is a common financial tool for publicly traded companies like Intelligent Bio Solutions, enabling them to raise funds efficiently without the need for a traditional secondary offering, which can be more time-consuming and costly. By leveraging this approach, INBS can issue new shares directly into the market through a designated sales agent, allowing for a more controlled and potentially less dilutive capital raise. This flexibility is particularly valuable for a medical technology company operating in a rapidly evolving sector, where timely access to capital can accelerate product development, regulatory approvals, and market expansion.

Intelligent Bio Solutions has positioned itself at the forefront of medical diagnostics by delivering rapid, non-invasive testing solutions that combine intelligent technology with user-friendly applications. The company's focus on innovation in medical testing aligns with growing healthcare demands for faster, more accurate, and less invasive diagnostic tools. The proceeds from this ATM offering will likely be utilized to enhance research and development efforts, expand manufacturing capabilities, and support commercialization strategies, all of which are critical for maintaining competitive advantage in the medical technology industry.

This funding announcement comes at a time when the healthcare sector is experiencing increased investment interest, driven by technological advancements and the ongoing need for improved diagnostic methods. Intelligent Bio Solutions' ability to tap into public markets through an ATM offering reflects investor confidence in its business model and growth prospects. Additionally, the company's Nasdaq listing provides it with the regulatory framework and visibility necessary to attract institutional and retail investors alike.

The implications of this capital raise extend beyond immediate financial benefits. By securing up to $10 million through an ATM offering, Intelligent Bio Solutions can sustain its innovation pipeline and potentially accelerate the rollout of new testing products. This could enhance patient outcomes by providing quicker and less invasive diagnostic options, ultimately contributing to better healthcare delivery. Furthermore, the company's strategic use of Nasdaq's ATM rules demonstrates a prudent approach to capital management, balancing shareholder interests with the need for ongoing investment in technology and market presence.

In summary, Intelligent Bio Solutions' $10.0 million at-the-market private placement marks a pivotal step in its growth trajectory. The company's focus on intelligent, rapid, non-invasive testing solutions positions it well within the expanding medical technology landscape. Through this flexible financing mechanism, INBS aims to strengthen its operational capabilities, advance product innovation, and deliver enhanced value to its stakeholders in the competitive healthcare market.